ALXO vs BZAI Comparison

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Blaize Holdings Inc provides transformative artificial intelligence (AI)-enabled edge computing solutions comprised of both its proprietary hardware and software, and third-party hardware solutions. Its portfolio includes programmable AI processors in various form factors, which can be deployed across sectors such as smart cities, defense, retail, and enterprise markets. The company operates as a single operating and reportable segment. The majority of the company's revenue is derived from Hardware revenue, which includes the sale of its semiconductor products and/or third-party hardware products that support semiconductor products through various supply agreements. Geographically, it generates the maximum revenue from China.